Oxford Biomedica (LON:OXB) Shares Down 14.6% – What’s Next?

Oxford Biomedica plc (LON:OXB) shares fell 14.6% during trading on Friday . The stock traded as low as GBX 441.50 and last traded at GBX 505. 6,604,510 shares changed hands during mid-day trading, an increase of 638% from the average daily volume of 895,491 shares. The stock had previously closed at GBX 591.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on OXB shares. Jefferies Financial Group restated a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Royal Bank Of Canada cut their price target on shares of Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 669.85.

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. The stock has a market capitalization of £611.24 million, a PE ratio of -18.76 and a beta of 1.12. The stock’s 50 day moving average is GBX 601.87 and its two-hundred day moving average is GBX 649.47.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.